Ethical quandaries around expanded carrier screening in third party reproduction

Given the limited benefits and important drawbacks of expanded carrier screening for gamete donors, a credible argument for a moral obligation to perform expanded screening cannot be made.
Ethical quandaries around expanded carrier screening in third party reproduction

Volume 109, Issue 2, Pages 190–194


Heidi Mertes, Ph.D., Steven R. Lindheim, M.D., M.M.M., Guido Pennings, Ph.D.


Although current screening methods of gamete donors are capable of reducing the incidence of genetic anomalies in donor offspring below general population levels, targeted screening for a large number of conditions (expanded carrier screening or ECS) could be considered as part of the routine selection procedure for gamete donors. There are, however, important drawbacks to its practical implementation. Excluding all carriers of severe recessive monogenic pediatric disorders would disqualify virtually all donors, and other approaches negatively affect cost (and therefore access), present dilemmas in regard to disclosure of genetic findings, and/or overburden the intended parents. In all of the scenarios considered, adequate genetic counseling will be of central importance. Besides looking at benefits and drawbacks of possible ways of implementing ECS, we also examine whether a moral obligation exists to adopt ECS at all and on whose shoulders such an alleged obligation would rest: policymakers, medical staff at fertility clinics, sperm and egg banks, the intended parents? We argue that given the small risk reduction brought about by ECS, the possible negative effects of its implementation, and the absence of widespread preconception carrier screening in the general population, it is inconsistent to argue that there is a moral obligation to perform ECS in the context of donor conception. Finally, implications for the donors are discussed.

Read the full text here.

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.

Go to the profile of Steven R. Lindheim, MD, MMM
over 4 years ago

I applaud the authors for their thoughtful insights into this controversial topic.  Screening oocyte donors for a Trio Panel vs ECS remains a challenge in our practice.  Full disclosure remains the easiest of algorithms, but industry standards would assist all of us.